0: Disease activity for participants with DLE or SCLE was evaluated using Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 41 and a Physician Global Assessment.
1: Procedure-related adverse events (AEs) and serious AEs were monitored and recorded.
